EL7.AI
StocksMedium•9 November 2026•
3 min read

Paysign Revenue Rises to $28.25 Million in Second Quarter of 2026

Key Facts

1Paysign revenue was $28.25 million in the second quarter of 2026, up 48.1% year over year.
2Pharmaceuticals revenue reached $14.65 million, up 88.9% year over year, with a net 51 programs added in the 12 months before the end of the quarter.
3The plasma segment recorded revenue of $13.04 million, up 21.4% year over year.
4The company raised its 2026 revenue outlook range to $114–117 million.

Paysign revenue reached about $28.25 million in the second quarter of 2026, up 48.1% from the same period in 2025, according to results filed with the U.S. Securities and Exchange Commission. The pharmaceuticals business was the faster-growing driver, with revenue rising to $14.65 million, up 88.9% year over year. By comparison, plasma revenue was $13.04 million, an annual increase of 21.4%. The results show expansion in both businesses, with pharmaceuticals growing faster than plasma. The figures were announced as the company raised its financial outlook for 2026.

The company attributed growth in pharmaceuticals revenue to the financial contribution of new patient assistance programs, adding a net 51 programs in the 12 months before the end of the second quarter. Paysign said segment revenue rose 88.9% to $14.65 million, compared with $7.75 million in the second quarter of 2025. The financial contribution of these programs includes management and setup fees, claims processing and other billable services, according to the company’s filing. This provides context for pharmaceuticals revenue growing faster than plasma revenue during the period. These figures relate to the second quarter of 2026, not the third quarter.

In the plasma business, revenue was $13.04 million in the second quarter, up 21.4% from the corresponding period a year earlier. But the net number of plasma centers fell by 46 in the 12 months before the end of the quarter, according to the filing. This places the segment’s revenue growth alongside a decline in its center count, without changing the fact that the segment recorded an annual increase in revenue. The comparison highlights different growth paths for the two businesses: pharmaceuticals grew 88.9%, while plasma revenue increased 21.4%. The company reported these indicators as part of its published second-quarter results.

Paysign reported second-quarter 2026 GAAP net income of $6.76 million, or $0.11 per fully diluted share. In the second quarter of 2025, net income was $1.39 million, or $0.02 per fully diluted share, according to the filing. Comparing the two periods shows earnings growth alongside revenue expansion, without conflating second-quarter figures with results expected for the following period. These were published historical quarterly figures, not third-quarter results. The filing cited here did not provide a comparison with analysts’ expectations for the third quarter.

The company raised its outlook for 2026, setting a revenue range of $114 million to $117 million and an adjusted EBITDA range of $35 million to $38 million. Paysign tied the outlook to its full-year performance in its second-quarter results announcement. The figures provide a company-issued financial benchmark for the year, but do not by themselves establish the results of any subsequent quarter. The company had announced on October 13, 2026, that it would host a call to discuss its third-quarter results. Within the facts reported here, the call date remains the available information about the next step in announcing those results.